FIT screening

The FIT-based screening test is easy and therefore manages to attract high participation rates – the main driver behind the success of any national or regional screening programme. Generally, national or regional administrations assume responsibility for managing the logistics, financials and efficiency of the programme in close cooperation with their selected laboratory partners.

For further information, you can check our FIT for screening microsite. 
www.fitscreening.eu/

 

 

Sysmex Europe GmbH organises a blood donation and sport event on 3 December With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement Blutspendeaktion bei Sysmex – 70 Blutspende-Helden zum 50. Firmenjubiläum Sysmex Launches Revohem FIX Chromogenic, a Blood Coagulation Factor IX Measurement Kit Sysmex Launches their First Subsidiary in Egypt and North Africa Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization CALiaGold – The new quantitative immunoassay from Sentinel Diagnostics for calprotectin measurement in SENTiFIT 270 Analyser Rozvoz zboží v průběhu vánočních svátků a na přelomu roku 2018/2019 Конференция в городе Благовещенске Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers VII Межрегиональная Научно-практическая конференция "Розовая Лента" Congratulations to our CEO Hisashi Ietsugu! Sysmex slaví půl století od založení! Конференция «Совершенствование организации онкологической и гематологической помощи населению в свете майских указов президента В.В. Путина 2018. Инновационные подходы к диагностике и лечению в онкологии» Die neue Ausgabe unseres Kundenmagazins Xtra ist da! Strengthening Our Global R&D Structure to Foster Early-Stage Innovation Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers In vitro diagnostics company Sysmex Europe announces executive leadership change Sysmex Inostics announces launch of OncoBEAM™ EGFR Kit v2 (RUO) in Europe and Asia Sysmex, Toppan Printing, and RIKEN GENESIS Commence Launch of Fully Automated System (Research Use Only) to Detect Gene Mutations in Cancer Tissue Sysmex Partec’s CyFlow™ Counter System, a System to Test for CD4+ Lymphocytes, Receives WHO Prequalification Sysmex and JVCKENWOOD Jointly Establish Company to Use Micro and Nano-Fabrication Technology to Develop and Manufacture IVD Biodevices Clinical evaluation of Sysmex Inostics’ plasma NGS liquid biopsy technology to complement mammography when screening for early stage breast cancer presented at the 2018 ASCO annual meeting Sysmex Establishes Subsidiary in Egypt and Begins Conducting Direct Sales and Services Sysmex, the Foundation for Biomedical Research and Innovation at Kobe, and Kyoto University Begin Joint Research on Technologies for Diagnosing Immunological Diseases CytoCell und weitere Oxford Gene Technology Produkte bei Sysmex erhältlich

Curious about our events?

Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
SUSPECTED HUS IN ROUTINE ANALYSIS
See the Podcast